Divalproex Sodium
Product Images NDC 0615-8327

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 0615-8327). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Divalproex Sodium Dr Tabs 125mg 250 mg 500mg 8326 1)

Chemical structure of divalproex sodium, showing the sodium salt form of the valproic acid dimer with carboxylate groups and hydrocarbon chains. The image depicts the molecular connectivity and the charged sodium ion.*

FDA Label Image

Principal Display Panel (Divalproex Sodium Dr Tabs 125mg 250 mg 500mg 8326 10)

Divalproex Sodium DR Tab USP 500 mg label sheet with multiple identical drug labels showing product name, strength, dosage form, lot number, expiration date placeholder, and barcode. The labels indicate packaging by Vangard, Glasgow, KY 42141. A separate section includes patient information, storage instructions, quantity of 30 tablets, and manufacturing details by Upsher-Smith, repackaged by Vangard Labs.*

FDA Label Image

Figure 1 (Divalproex Sodium Dr Tabs 125mg 250 mg 500mg 8326 2)

A bar chart comparing percentages between placebo (PBO) and Divalproex Sodium (DVPX) in two studies. Study 1 (YMRS) shows approximately 26% for PBO and 60% for DVPX, while Study 2 (MRS) shows about 29% for PBO and 58% for DVPX. The vertical axis represents percentage values from 0% to 70%.*

FDA Label Image

Figure 2 (Divalproex Sodium Dr Tabs 125mg 250 mg 500mg 8326 3)

A line graph showing the percentage reduction in CPS rate plotted against the percentage of patients. Two curves compare Divalproex sodium and placebo, indicating improvement or worsening. The vertical axis represents improvement (up) and worsening (down) in CPS rate, while the horizontal axis shows the percentage of patients from 100% to 0%.*

FDA Label Image

Figure 3 (Divalproex Sodium Dr Tabs 125mg 250 mg 500mg 8326 4)

A cumulative distribution graph showing the percentage of patients versus the percentage reduction in CPS (complex partial seizures) rate for Divalproex Sodium. The graph compares high dose (solid line) and low dose (dashed line) treatment groups, indicating changes from worsening to improvement in seizure rate reduction.*

FDA Label Image

Figure 4 (Divalproex Sodium Dr Tabs 125mg 250 mg 500mg 8326 5)

A bar chart comparing Placebo and Divalproex Sodium in two separate studies labeled Study 1 and Study 2. The vertical axis measures an unspecified quantity ranging from 0 to 6, with Placebo bars higher than the corresponding Divalproex Sodium bars in both studies.*

FDA Label Image

Principal Display Panel Divalproex Sodium Dr Tabs 125 mg Bingo (Divalproex Sodium Dr Tabs 125mg 250 mg 500mg 8326 6)

Label for Divalproex Sodium DR Tabs USP 125 mg by NCS HealthCare of KY, LLC dba Vangard Labs. The label shows the product name, strength, and dosage form with Lot 8326 and space for expiration date. It specifies storage at controlled room temperature (20°-25°C) and instructions to swallow whole. The quantity listed is 30 tablets. Manufacturer is Upsher-Smith with packaging by Vangard in Glasgow, KY.*

FDA Label Image

Principal Display Panel Divalproex Sodium Dr Tabs 250 mg Bingo (Divalproex Sodium Dr Tabs 125mg 250 mg 500mg 8326 7)

Divalproex Sodium DR Tabs USP 250 mg label showing packaging and lot information. The label notes manufacture by Upsher-Smith with packaging by Vangard Labs in Glasgow, KY. It includes storage instructions, barcode, and institutional use statement. The package size is 30 tablets with directions to see the patient information on the reverse.*

FDA Label Image

Principal Display Panel Divalproex Sodium Dr Tabs 250 mg Unit-dose (Divalproex Sodium Dr Tabs 125mg 250 mg 500mg 8326 8)

Packaging label for Divalproex Sodium DR tablets USP 250 mg from NCS HealthCare of KY, LLC dba Vangard Labs. The label displays multiple repeated sections showing the drug name, dosage strength, lot number placeholder, expiration placeholder, and a barcode. The bottom section includes detailed packaging information, dosage form, quantity of 30 tablets, storage instructions, and manufacturer details listed as Upsher-Smith with repackaging by Vangard Labs, Glasgow, KY.*

FDA Label Image

Divalproex 500mg Dr Tabs Bingo Card Label (Divalproex Sodium Dr Tabs 125mg 250 mg 500mg 8326 9)

Label of Divalproex Sodium DR Tabs USP 500 mg tablets, manufactured by Upsher-Smith and packaged by Vangard Labs in Glasgow, KY. The label includes lot number 8328, quantity of 30 tablets, storage instructions at 20°-25°C, and a note that each tablet contains Divalproex Sodium equivalent to 500 mg valproic acid. The label also features barcodes and a date tracking grid for institutional use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.